Tarceva (Trademark) (erlotinib HCl, OSI-774)

DRUG2 trials

Sponsors

OSI Pharmaceuticals

Conditions

Advanced Non Small Cell Lung CancerFailed Prior ChemotherapyNon-Small Cell Lung Cancer

Phase 2

Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

CompletedNCT00072631

OSI PharmaceuticalsAdvanced Non Small Cell Lung Cancer, Failed Prior Chemotherapy

Start: 2003-11-05End: 2007-03-14Updated: 2018-02-08

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

CompletedNCT00085839

OSI PharmaceuticalsNon-Small Cell Lung Cancer

Start: 2004-02-29End: 2007-03-31Updated: 2012-08-09